Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New MEK inhibitors and their use patented

Sep. 2, 2003

PSA-activated thapsigargin prodrug as a specific agent for prostate cancer

Sep. 2, 2003

JIMB-01, a microtubule-modifying agent, has antiproliferative properties in human malignant tumors

Sep. 2, 2003

Enrollment commences in phase I trial of Dacogen plus Proleukin for cancer

Sep. 1, 2003

NICE recommends first-line treatment with Glivec for newly diagnosed CML patients

Sep. 1, 2003

Potent and selective CDK4 inhibitors identified by Warner-Lambert researchers

Sep. 1, 2003

New tyrosine kinase inhibitors in early development at Novartis

Aug. 29, 2003

Orphan drug designation for glioma drug 131I-TM-601

Aug. 29, 2003

Long-lasting tumor responses seen in phase II NHL study of pixantrone

Aug. 28, 2003

KRN-5500 shows significant activity against CLL cells in vitro

Aug. 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...